Eiger Investor News

Home»Eiger Investor News
7 05, 2020

Eiger BioPharmaceuticals Reports First Quarter 2020 Financial Results and Provides Business Update

2020-05-07T20:42:20+00:00

Eiger BioPharmaceuticals Reports First Quarter 2020 Financial Results and Provides Business Update PALO ALTO, Calif. May 7, 2020 — Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today reported financial results for first quarter 2020 and provided a business update. “We achieved key milestones [...]

Eiger BioPharmaceuticals Reports First Quarter 2020 Financial Results and Provides Business Update2020-05-07T20:42:20+00:00
17 04, 2019

Eiger BioPharmaceuticals Announces Pricing of Public Offering of Common Stock – 4/17/2019

2019-04-18T13:23:00+00:00

Eiger BioPharmaceuticals Announces Pricing of Public Offering of Common Stock - 4/17/2019 Palo Alto, Calif., April 17, 2019, Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR) today announced the pricing of an underwritten public offering of 4,500,000 shares of its common stock at a price to the public of $11.00 per share. All of the shares are being [...]

Eiger BioPharmaceuticals Announces Pricing of Public Offering of Common Stock – 4/17/20192019-04-18T13:23:00+00:00
17 04, 2019

Eiger BioPharmaceuticals Announces Proposed Public Offering of Common Stock 4/17/2019

2019-04-18T13:18:13+00:00

Eiger BioPharmaceuticals Announces Proposed Public Offering of Common Stock 4/17/2019 Palo Alto, Calif., April 17, 2019, Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR) today announced that it has commenced an underwritten public offering of shares of its common stock. All of the shares to be sold in the offering are to be sold by Eiger. In [...]

Eiger BioPharmaceuticals Announces Proposed Public Offering of Common Stock 4/17/20192019-04-18T13:18:13+00:00